Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moleculin BiotechMBRX +4.98%30 EV-to-OCF is 0.29 as of Aug. 10, 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, Moleculin Biotech ranks worse than 74.52% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Moleculin Biotech's Enterprise Value is $-6.94 Mil.
Moleculin Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-24.28 Mil. Therefore, Moleculin Biotech's EV-to-OCF for today is 0.29.
The historical rank and industry rank for Moleculin Biotech's EV-to-OCF or its related term are showing as below:
MBRX'
s EV-to-OCF Range Over the Past 10 Years
Min: 0.28 Med: 0 Max: 0.29
Current: 0.29
During the past 11 years, the highest EV-to-OCF of Moleculin Biotech was 0.29. The lowest was 0.28. And the median was .
MBRX's EV-to-OCF is ranked worse than 74.52% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs MBRX: 0.29
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Moleculin Biotech's PE Ratio (TTM) for today is calculated as:
Moleculin Biotech's share price for today is $0.4304.
Moleculin Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-27.961.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Moleculin Biotech EV-to-OCF Related Terms
Moleculin Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Moleculin Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Moleculin Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's EV-to-OCF falls into.
Moleculin Biotech's current Enterprise Value is $-6.94 Mil.
Moleculin Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moleculin Biotech (MBRX) has a EV-to-OCF of 0.29 as of Aug. 10, 2026. Over the past decade, Moleculin Biotech's EV-to-OCF has ranged from 0.28 to 0.29. According to the industry distribution chart, Moleculin Biotech ranks #1047 out of 1405 companies in the Biotechnology industry, placing it in the top 74.5%.
Is Moleculin Biotech's EV-to-OCF too high?
Moleculin Biotech's current EV-to-OCF is 0.29. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.29. Based on the distribution chart, Moleculin Biotech ranks #1047 out of 1405 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's EV-to-OCF compare to AKTX and INTI?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #1047 out of 1405 companies for EV-to-OCF. This places Moleculin Biotech in the lower half of its industry. Historically, Moleculin Biotech's own EV-to-OCF has ranged from 0.28 to 0.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Moleculin Biotech's current EV-to-OCF is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current EV-to-OCF of 0.29. The current EV-to-OCF is 0.29. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current EV-to-OCF is 0.29 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score
Get the complete analysis for MBRX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 
